Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13251 - 13275 of 15151 in total
BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
Investigational
Matched Iupac: … 4-(4-{[(6-methoxy-2-{2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl}-1-benzofuran-4-yl)oxy]methyl}-1,3 …
Investigational
Matched Iupac: … N-(4-hydroxyphenyl)-3-{6-[(3S)-3-[(morpholin-4-yl)methyl]-1,2,3,4-tetrahydroisoquinoline-2-carbonyl]- …
Experimental
Experimental
99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect after treatment with 99mTc 14F7 Mab.
Investigational
Matched Description: … Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor …
Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.[L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
Investigational
Matched Description: … [L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by …
MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1 antibody.
Investigational
Matched Description: … Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and
RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors).
Investigational
Matched Description: … is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and
FB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells. It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).[A258448,L45743]
Investigational
Matched Description: … It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin …
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection . It...
Investigational
Matched Description: … In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce ... These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and
Experimental
Matched Iupac: … (Z,6S)-N-[(2S,3R,6R,7R)-3-[(acetyloxy)methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]octan-7-yl]-6 …
Experimental
Matched Iupac: … 2-(2-{[(2E)-5-chloro-6-({[(1R)-1-(3-chlorophenyl)ethyl]carbamoyl}methyl)-1-hydroxy-1,2-dihydropyridin …
TAS-116 is under investigation in clinical trial NCT02965885 (A Study of TAS-116 in Patients With Solid Tumors).
Investigational
Matched Iupac: … 3-ethyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin …
CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). It was generated by HGS using the Abgenix XenoMouse technology.
Investigational
Matched Description: … CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor …
Zastumotide is a recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) also known as astuprotimut-R. It is under investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck).
Investigational
Matched Description: … clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and
Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)).
Investigational
Matched Description: … Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
Investigational
Matched Description: … anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and
Displaying drugs 13251 - 13275 of 15151 in total